News | November 03, 2011

Recovery Phase Of Treadmill Stress Test Unmasks Concealed Long QT Syndrome With High Accuracy

November 3, 2011 – New study indicates strong diagnostic ability of treadmill exercise stress testing to uncover Long QT syndrome (LQTS) in patients.  Here, investigators from the Mayo Clinic show how the recovery phase displays significant and maladaptive changes in the QTc unveiling the most common LQTS type, LQT1. The study, published in the November edition of HeartRhythm, the official journal of the Heart Rhythm Society, is the largest, single-center study of treadmill exercise stress testing in patients with genetically proven LQTS as well as those who were dismissed as normal.

Long QT syndrome affects about 1 in 2,500 individuals, and nearly 40 percent of patients with LQTS can have a nondiagnostic QTc at rest.  However, through treadmill stress testing, this new study reveals significant differences in QTc values for the three primary types of LQTS (LQT1-LQT3) at a specific moment in time during the exercise test.  QTc was calculated at rest, peak exercise and for the first five minutes of recovery.

Between 1998 and 2008, more than 1,000 patients with a referral diagnosis of LQTS were seen at the Mayo Clinic’s Long QT Syndrome Clinic in Rochester, Minn.  Of these patients, an Institutional Review Board-approved, retrospective analysis was performed on the treadmill stress test in 243 individuals including, 82 LQT1, 55 LQT2, 18 LQT3, and 88 genotype-negative patients (control group) dismissed as normal.   

Results of the treadmill exercise stress test reveal the following:

  • Maladaptive QTc prolongation during the recovery phase distinguishes LQTS, particularly LQT1 patients, from the control group. 
  • Specifically, patients with LQT1 most distinguished themselves from the other genotypes and the controls at 2 and 3 minutes of recovery.
  • Beta-blockers did not significantly obscure the response noted during the recovery phase, which eliminates the need for a beta-blocker washout.

Overall, even with nondiagnostic QTc at rest, a prolonged QTc (> 470 ms) seen in patients at 3 minutes of recovery provides at 75 percent pre-genetic test probability for LQT1.

“Our results refine and improve the diagnostic ability of treadmill stress tests during the evaluation of patients with possible long QT syndrome by showing precisely where the greatest diagnostic separation resides, the recovery phase,” stated lead author Michael J. Ackerman, M.D., Ph.D., director of Mayo Clinic’s Long QT Syndrome Clinic and the Windland Smith Rice Sudden Death Genomics Laboratory in Rochester, Minn.  “We hope that this targeted approach to reading and measuring the QTc will not only help to catch long QT syndrome when it is there, but to also help decrease the current rate of overdiagnosis of Long QT, which has resulted from misinterpretations of stress tests, and ultimately improve patients’ quality of life.”

Over the past two decades, other diagnostic tools used in the evaluation of LQTS have increased dramatically including genetic testing and provocative testing with catecholamines, like the epinephrine QT stress test.  However, unlike exercise stress tests, the epinephrine QT stress test is not available at many centers and without appropriate experience in detecting the LQT1 response during epinephrine, it can be challenging to interpret.  In contrast, exercise stress tests, such as treadmill testing, are more readily available at cardiology centers around the country.  As shown through this study, evaluating patients during the recovery phase of treadmill exercise testing can result in an accurate diagnosis of LQTS, and offers clinicians another approach to consider.

For more information: www.heartrhythmjournal.com

 

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init